May 6, 2022Open Access

ROS-responsive liposomes as an inhaled drug delivery nanoplatform for idiopathic pulmonary fibrosis treatment via Nrf2 signaling

Key Points

Key points are not available for this paper at this time.

Abstract

DTP@DMF NPs can reduce macrophage-mediated fibroblast-to-myofibroblast transition and extracellular matrix deposition to attenuate lung fibrosis by upregulating Nrf2 signaling. This ROS-responsive liposome is clinically promising as an ideal delivery system for inhaled drug delivery.

Bookmark

View Full Paper

Cite This Study

Liu et al. (Fri,) studied this question.

synapsesocial.com/papers/69e242a2a4df08bf76ad3e16 https://doi.org/https://doi.org/10.1186/s12951-022-01435-4

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1The chemokine system in diverse forms of macrophage activation and polarization2004 · 6,442 citations
2Tanshinone IIA attenuates silica-induced pulmonary fibrosis via Nrf2-mediated inhibition of EMT and TGF-β1/Smad signaling2020 · 125 citations
3A new biosafe reactive oxygen species (ROS)-responsive nanoplatform for drug delivery2016 · 61 citations
4Microcystin-LR ameliorates pulmonary fibrosis via modulating CD206+ M2-like macrophage polarization2020 · 195 citations
5Anti-PEG antibodies in the clinic: Current issues and beyond PEGylation2016 · 682 citations

Bookmark

View Full Paper